These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 25699270)

  • 1. Preformulation studies for generic omeprazole magnesium enteric coated tablets.
    Migoha CO; Ratansi M; Kaale E; Kagashe G
    Biomed Res Int; 2015; 2015():307032. PubMed ID: 25699270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation of multiparticulate systems as lyophilised orally disintegrating tablets.
    Alhusban F; Perrie Y; Mohammed AR
    Eur J Pharm Biopharm; 2011 Nov; 79(3):627-34. PubMed ID: 21693189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets.
    Storpirtis S; Rodrigues D
    Drug Dev Ind Pharm; 1998 Nov; 24(11):1101-7. PubMed ID: 9876567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the pharmaceutical quality of omeprazole capsule brands marketed in Egypt.
    El-Sayed A; Boraie NA; Ismail FA; El-Khordagui LK; Khalil SA
    East Mediterr Health J; 2007; 13(6):1427-37. PubMed ID: 18341192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissolution test for liquid formulations of omeprazole enteric-coated products.
    Jang HJ; Kang BC; Shin WG; Lee S
    Ann Pharmacother; 2003 Jan; 37(1):150-1. PubMed ID: 12503954
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of bicarbonate buffer systems for dissolution characterization of enteric-coated proton pump inhibitor tablets.
    Shibata H; Yoshida H; Izutsu K; Goda Y
    J Pharm Pharmacol; 2016 Apr; 68(4):467-74. PubMed ID: 27019275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tableting and stability evaluation of enteric-coated omeprazole pellets.
    Türkoğlu M; Varol H; Celikok M
    Eur J Pharm Biopharm; 2004 Mar; 57(2):279-86. PubMed ID: 15018985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
    Miner PB; Fort JG; Zhang Y
    Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations.
    Wang Y; Liu H; Liu K; Sun J; He Z
    Pharm Dev Technol; 2013; 18(2):401-6. PubMed ID: 22339279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a bionic system for the simultaneous prediction of the release/absorption characteristics of enteric-coated formulations.
    Liu W; He X; Li Z; Gao X; Ma Y; Xun M; Liu C
    Pharm Res; 2013 Feb; 30(2):596-605. PubMed ID: 23135820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison.
    Mohylyuk V; Yerkhova A; Katynska M; Sirko V; Patel K
    AAPS PharmSciTech; 2021 Jun; 22(5):188. PubMed ID: 34159427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation study for lansoprazole fast-disintegrating tablet. III. Design of rapidly disintegrating tablets.
    Shimizu T; Sugaya M; Nakano Y; Izutsu D; Mizukami Y; Okochi K; Tabata T; Hamaguchi N; Igari Y
    Chem Pharm Bull (Tokyo); 2003 Oct; 51(10):1121-7. PubMed ID: 14519914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of crystal habit of ibuprofen using the phase partition technique: effect of aerosil and tween 80 in binding solvent.
    Umprayn K; Luengtummuen A; Kitiyadisai C; Pornpiputsakul T
    Drug Dev Ind Pharm; 2001 Nov; 27(10):1047-56. PubMed ID: 11794807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of omeprazole pellets fabricated by sieving-spheronization and extrusion - spheronization process.
    Karim S; Baie SH; Hay YK; Bukhari NI
    Pak J Pharm Sci; 2014 May; 27(3):425-38. PubMed ID: 24811797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation, characterization and investigation of Cordia dichotoma fruit polysaccharide as a herbal excipient.
    Pawar HA; Jadhav P
    Int J Biol Macromol; 2015 Jan; 72():1228-36. PubMed ID: 25450544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bioavailability of two enteric-coated capsules of omeprazole in healthy volunteers.
    Garg SK; Chugh Y; Tripathi SK; Kumar N; Sharma PL
    Int J Clin Pharmacol Ther Toxicol; 1993 Feb; 31(2):96-9. PubMed ID: 8458683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of capsules containing omeprazole in enteric coated pellets.
    Palummo M; Cingolani A; Dall L; Volonté MG
    Boll Chim Farm; 2000; 139(3):124-8. PubMed ID: 10961022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.